Payer Management and Pricing Dynamics for Non-Oncology Pharmacy Benefit Orphan Drugs for Rare Diseases in the United States Launched 2004-2014

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1321
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy180 - Uk Health Technology Assessment of Orphan Drugs for Rare Oncology Versus Rare Disease: Does Orphan Designation Make Any Difference in Hta Process?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

Value and Payment for Oncology in the United States

Annales Pharmaceutiques Francaises
PharmacologyPharmaceutical Science
2013English

Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Trends in Approvals and Prices of Oncology Drugs in the United States (1990-2013)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

A Proposed Definition of Rare Diseases for China: From the Perspective of Return on Investment in New Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2015English

Prices Analysis of Osteoporosis Drugs Marketed in the United States (1988-2014)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy